Shari Ommert
Papers
1
Total Citations
4
H-Index
1
About
Shari Ommert is a researcher whose work has centered on advancing early-stage drug discovery through innovative assay development, particularly in the critical area of ADME/Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) screening. Her most cited contribution, the 2003 paper "ADMET Assays on Tecan's LabCD-ADMET System," details the successful adaptation of three pivotal assays—Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—onto a novel microfluidic platform. This work was instrumental in demonstrating how miniaturization and automation could accelerate the profiling of drug candidates, a key bottleneck in the development pipeline. While her citation count of 4 reflects a focused, specialized contribution, its impact lies in its pioneering application of lab-on-a-chip technology for pharmacokinetic screening. Ommert’s research helped bridge the gap between high-throughput screening and physiologically relevant ADME data, offering a practical solution for early elimination of problematic compounds. Her efforts underscore the importance of method validation in translational bioanalysis, providing a foundation for more efficient, cost-effective drug development workflows that remain relevant to researchers in pharmaceutical sciences today.
Research Focus
Key Achievements
Top Papers
- 1ADMET Assays on Tecan's LabCD-ADMET System4 citations · 2003